September 28, 2010
Phase 3 trial of Sutent for advanced castration-resistant prostate cancer (CRPC)Pfizer announced the discontinuation of the SUN 1120 Phase 3 trial evaluating Sutent (sunitinib malate) in combination with prednisone for men with advanced castration-resistant prostate cancer (CRPC) that had progressed despite treatment with a docetaxel-based chemotherapy regimen. During a scheduled interim analysis, an independent Data Monitoring Committee (DMC) found that the combination of sunitinib with prednisone was unlikely to improve overall survival when compared to prednisone alone. No new or unexpected safety issues were identified.
Sutent is an oral multi-kinase inhibitor approved for the treatment of gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate and advanced / metastatic renal cell carcinoma (RCC).
For more information call (800) 438-1985 or visit www.pfizer.com.